Zentalis Pharmaceuticals Inc. (ZNTL): Price and Financial Metrics
ZNTL Price/Volume Stats
| Current price | $1.38 | 52-week high | $9.52 |
| Prev. close | $1.46 | 52-week low | $1.01 |
| Day low | $1.36 | Volume | 225,797 |
| Day high | $1.43 | Avg. volume | 1,327,665 |
| 50-day MA | $1.32 | Dividend yield | N/A |
| 200-day MA | $2.46 | Market Cap | 98.93M |
ZNTL Stock Price Chart Interactive Chart >
Zentalis Pharmaceuticals Inc. (ZNTL) Company Bio
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.
ZNTL Price Returns
| 1-mo | 15.97% |
| 3-mo | -22.03% |
| 6-mo | -55.34% |
| 1-year | -85.50% |
| 3-year | -93.63% |
| 5-year | -96.71% |
| YTD | -54.46% |
| 2024 | -80.00% |
| 2023 | -24.78% |
| 2022 | -76.04% |
| 2021 | 61.84% |
| 2020 | N/A |
Loading social stream, please wait...